Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) and combination therapy led to a significant decrease in mean glycated hemoglobin (HbA1c) levels by −3.5% at 12 months compared to DPP-4 inhibitors.
Practitioners can consider GLP-1RAs and combination therapy as effective options for managing HbA1c in liver transplant recipients with diabetes.
StrongSupportsmedium confidence
Combination therapy remained significant when adjusted for DPP‐4 inhibitor treatment (−3.5%, 95% CI [−6.1, −0.95]; p = 0.0089) at 12 months.
Why this rating
The study is based on a retrospective analysis of prospectively collected data.
Source
<scp>Glucagon‐like peptide</scp> ‐1 receptor agonists and <scp>sodium‐glucose cotransporter</scp> ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
Katina Zheng et al. · Diabetes Obesity and Metabolism · 2024
cohort · n=362Cited 13×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →